Hot Features
Vaxil Bio Ltd., a biotechnology company, focuses on a novel drug discovery and development platform based on signal peptides for infectious diseases and cancer. Its lead product candidate is ImMucin, a MUC1 SP-based vaccine that has completed a Phase 1/2 clinical trial for the treatment of multiple ... Vaxil Bio Ltd., a biotechnology company, focuses on a novel drug discovery and development platform based on signal peptides for infectious diseases and cancer. Its lead product candidate is ImMucin, a MUC1 SP-based vaccine that has completed a Phase 1/2 clinical trial for the treatment of multiple myeloma. The company is headquartered in Toronto, Canada. Show more
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 12 | -0.0753 | -77.3100616016 | 0.0974 | 0.5 | 0.021 | 6286 | 0.13558778 | CS |
| 26 | -0.0579 | -72.375 | 0.08 | 0.5 | 0.011 | 4130 | 0.12157491 | CS |
| 52 | -0.0893 | -80.1615798923 | 0.1114 | 0.5 | 0.0021 | 3267 | 0.10353111 | CS |
| 156 | 0.0101 | 84.1666666667 | 0.012 | 0.5 | 0.0001 | 33863 | 0.01098988 | CS |
| 260 | -0.051546 | -69.9915813486 | 0.073646 | 0.5 | 0.0001 | 45610 | 0.03906081 | CS |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
Vous avez déjà un compte? Connexion
Vous n'avez pas de compte ? Inscription
En m'inscrivant, je confirme avoir lu, compris et accepté les Conditions générales d'ADVFN et j'affirme etre un investisseur privé.